Publications by authors named "Isabela Hellmann Acras"
Int J Obes (Lond)
January 2025
Article Synopsis
- Semaglutide, a GLP-1 receptor agonist, helps reduce blood sugar levels and weight in overweight or obese individuals, and the study aimed to assess its impact on cardiovascular outcomes and side effects.
- After reviewing a total of 38 studies, results showed that semaglutide significantly decreased risks of hospitalization for heart failure, cardiovascular-related deaths, and other serious heart conditions.
- The conclusion indicates that while semaglutide effectively reduces various cardiovascular risks, it also comes with a higher relative risk of experiencing adverse effects compared to some other treatments.
